References: Adult dermatomyositis

Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csorgo Z, Dimachkie MM, Griger Z, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 2022;387(14):1264-78. https://www.ncbi.nlm.nih.gov/pubmed/36198179
DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol 2020;82(2):267-81. https://www.ncbi.nlm.nih.gov/pubmed/31279808
Ig Governance. Inflammatory myopathies: polymyositis (PM), dermatomyositis (DM) and necrotising autoimmune myopathy (NAM) version 3.2. Criteria for clinical use of immunoglobulin in Australia. Canberra: National Blood Authority. 2020; Accessed Nov 2022. https://www.criteria.blood.gov.au/MedicalCondition/View/2616
Schmidt J. Current Classification and Management of Inflammatory Myopathies. J Neuromuscul Dis 2018;5(2):109-29. https://www.ncbi.nlm.nih.gov/pubmed/29865091
Takanashi S, Kaneko Y, Takeuchi T. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review. Mod Rheumatol 2022;32(1):231-7. https://pubmed.ncbi.nlm.nih.gov/33769925/
Waldman R, DeWane ME, Lu J. Dermatomyositis: Diagnosis and treatment. J Am Acad Dermatol 2020;82(2):283-96. https://www.ncbi.nlm.nih.gov/pubmed/31279813